By Fineline Cube 
US‑based Bristol-Myers Squibb (BMS; NYSE: BMY) delivered its third‑quarter 2025 earnings, showing a modest 2% year‑on‑year lift in global sales to USD 12.2 billion on a constant‑currency basis. The performance of its flagship Growth Portfolio was a key catalyst, underlined by standout gains in CAR‑T therapy, anemia treatment, and cardiac precision medicine.
Revenue Breakdown
| Market | Q3 2025 Sales | YoY % Change | Currency‑Adjusted |
|---|---|---|---|
| United States | USD 8.3 billion | +1 % | |
| International | USD 3.9 billion | +3 % | |
| Total | USD 12.2 billion | +2 % |
- Global growth driven across both domestic and international arenas.
- International sales grew slightly faster at 3 % versus 1 % in the US.
Growth Portfolio Dominates
The Growth Portfolio brought 17 % growth during the quarter, accounting for USD 6.9 billion of total revenue. Key contributors were:
- Breyanzi (lisocabtagene maraleucel) – +58 % to USD 359 million
- Reblozyl (luspatercept) – +37 % to USD 615 million
- Camzyos (mavacamten) – +88 % to USD 296 million
- Opdivo (nivolumab) – +6 % to USD 2.53 billion
- Yervoy (ipilimumab) – +14 % to USD 739 million
These product milestones underscored BMS’s balanced pipeline across immuno‑oncology and niche specialties.
Updated Full‑Year Guidance
Buoyed by the robust Growth Portfolio, BMS has nudged its annual revenue outlook higher:
- Forecasted FY2025 Sales: USD 47.5‑48.0 billion
- Prior Guidance: USD 46.5‑47.5 billion
The lift reflects confidence in sustained demand for its high‑margin products and the company’s strategic product expansion.
Investor Takeaway
BMS’s ability to generate consistent growth across both its traditional and emerging therapy segments positions it as a durable player in the biopharma space. Market watchers will continue to monitor the trajectory of the Growth Portfolio, particularly the long‑haul performance of Breyanzi and Camzyos, as these products contribute significantly to the company’s revenue acceleration.-Fineline Info & Tech